KLK3 and prostate cancer: 2004; Weichert et al. 2008). Consequently, HDAC function has been considered a potential therapeutic target for prostate cancer treatment. Clinical studies with HDAC inhibitors have shown significantly decreased levels of prostate-specific antigens (PSAs) in some patients (Munster et al. 2009).